Videos

Real-world data show tear film and Schirmer improvements with two preservative-free dry eye drops at ESCRS 2026.

Suzana Konjevoda, MD, previews ESCRS 2026, highlighting new IOLs, presbyopia correction, AI in everyday practice, and advances in post-cataract surgery recovery and comfort.

Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye programme.

Andrew G. Lee, MD, and Drew Carey, MD, break down a debate over PDE-5 inhibitor use after non-arteritic anterior ischemic optic neuropathy.

A VR lens simulator used at InVision Eye Care lifted premium IOL conversion rates from 30%-35% to the mid-40s

Ashraf Ahmad, MD, explains what tear breakup time testing shows and why results vary between clinic visits.

Douglas D. Koch, MD, and Julie Schallhorn, MD, MS, discuss the optical designs behind EDOF lenses, where they fit in clinical practice, and advances shaping the category.

Amy Zhang, MD, discusses coverage barriers to home IOP monitoring, a surgical ergonomics habit for early-career surgeons, and glaucoma's role in burnout.

Amy Zhang, MD, on why self-care alone won't fix physician burnout and what health systems need to address instead.

Host Deborah G. Ristvedt, DO, welcomes Dr. Berdahl to discuss the formative experiences, entrepreneurial drive, and personal philosophy that have shaped his career as a surgeon, innovator, and mentor.

Capsulotomy size may not be refractive neutral: a larger opening shifted the IOL about 120 µm posteriorly in thin lenses and anteriorly in thick ones in a paired-eye study.

Andrew G. Lee, MD, and Drew Carey, MD, discuss a study exploring whether these two conditions are really one disease—and what that means for long-term treatment.

Real-world SPECTRUM data shows strong fluid resolution and vision gains by week 12, with low adverse events and no retinal vasculitis.

Real-world Spectrum data show aflibercept 8 mg boosts early vision and retinal anatomy in wet AMD, including switch patients.

Learn how missed follow-ups and insurance hurdles limit retinal anti-VEGF care—and the strategies clinicians use to keep patients treated.

Clinicians unpack anti‑VEGF access barriers—missed visits, step therapy, costs—and how bevacizumab and assistance programs keep patients treated.

Exploring ranibizumab port delivery: long-lasting anti-VEGF control, but surgery, access hurdles and safety tradeoffs make patient selection crucial.

Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.

Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.

Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.

Ranibizumab port system delivers anti‑VEGF durability, but surgical risks, access hurdles and patient selection limit wider use.

See how retina experts set anti-VEGF intervals: loading doses, OCT-based treat-and-extend, and why 4-month claims don’t fit all.

Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.

How faricimab reshapes DME care: trial vs real-world durability, Ang2/VEGF clues, when to switch, and how AI-guided OCT may help.

Clinical and real-world faricimab data reshape DME treatment strategies, highlighting durability, drying benefits, and when switching therapies may improve outcomes.

Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.

Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.

New aflibercept 8 mg label expands dosing from every 4 to 20 weeks, boosting flexibility, insurance support, and outcomes in tough retinal cases.